Seeking Alpha
View as an RSS Feed

Ang Nguyen  

View Ang Nguyen's Comments BY TICKER:
Latest  |  Highest rated
  • Monster Beverage To Follow The Lead Of Green Mountain Coffee Roasters? [View article]
    You are missing the point. Monster is a company that is driven primarily by one product line. Of course there is global upside, but competition continues to rise and all of its competitors are seeking global growth..

    I am not suggesting that its products are bad, but after many years of gains, investors are starting to lose confidence and the company needs a new edge. Regardless of whether or not it led to the death of anyone it still changes the perception of people, which is the most important factor.

    The comparison to GMCR was made because GMCR was a momentum stock for many years, continued to post record sales, but traded in a free fall before finally finding support. The company has had to evolve. It began to announce partnerships and a focus on healthy alternatives, and some are now optimistic of its future.

    We live in a health conscious society. The fastest growing companies are those that can find the balance between healthy and tasteful. In order to quiet the critics Monster should begin to incorporate healthy all-natural ingredients to its products, and more people will gravitate and choose its products over the competition. It needs to be ahead of this curve, rather than behind. All of the large beverage companies are making this change to their lead products, Monster needs to get aggressive and quiet the critics.

    Like it or not, there are allegations. Who knows whether or not it's true. But at this point, some people won't care or take the chance. The company needs to make a big splash, somehow.
    Nov 5, 2012. 06:25 PM | Likes Like |Link to Comment
  • 3 Companies That Could Soar On Massive Stevia Market Opportunities [View article]
    It has been pointed out to me that I have a transposed number within the article that needs corrected. The second sucrose modifier is S9632, not S6932. My apologies for the error.
    Oct 12, 2012. 10:29 PM | Likes Like |Link to Comment
  • 3 Companies That Could Soar On Massive Stevia Market Opportunities [View article]
    I understand your concern with the company and at first glance it doesn't look like a fundamentally sound investment based on financial statements alone. The company fully disclosed Mr Dhillon's, in SEC documents, relationship and ties to the land lease. The going rate of $125/acre is well within the cost associated with land in the area, and keep in mind, that the fact that it meets all zoning requirements necessary for progress could have gotten a larger premium.

    And you are corect, that at present time they have no product to sell. That is usually the case in most start up companies, but you are ignoring the fact that Stevia First has a solid leadership team in place and are creating an infrastructure for long term success. They have contracted with several industry leaders whose expertise is well documented.

    I have disclosed that I have a position in STVF and I want to see them do well
    Oct 12, 2012. 09:44 AM | 1 Like Like |Link to Comment
  • Nokia Lumia 920: Great Phone, Wrong Marketing [View article]
    The Lumia 920 may be a great phone, but I believe its the operating system that will hold back its potential and sales. The smartphone market is dominated by Android and Apple because of the apps available from those platforms.
    Sep 6, 2012. 01:31 PM | 1 Like Like |Link to Comment
  • Starbucks Adding Stevia To Their Energy Drinks May Be A Boost For Stevia Growers [View article]
    STVF seems to have a great leadership team in place. The addition of adding Vineland and Jim Brandle to the mix gives them immense credibility. The trend for natural products has been growing and a zero to low calorie sweetener will be welcomed by the consumer market and investors.
    Sep 6, 2012. 12:29 PM | 1 Like Like |Link to Comment
  • Coca-Cola: The Correction Has Just Begun [View article]
    I am long KO and have been for quite some time. They have been a solid performer for me and if they hit $35, which I don't anticipate any time soon, I will be adding to my portfolio.
    Sep 6, 2012. 12:23 PM | Likes Like |Link to Comment
  • Isotopes, Shortages, Solutions & The Growing Demand Of Cancer Treatment [View article]
    Good informative article. I see the potential in investing in radioisotope providers and agree that this could be an area that returns solid gains in the very near future.
    Aug 14, 2012. 02:32 PM | 1 Like Like |Link to Comment
  • ImmunoCellular Therapeutics And The Benefits Of A Large Exchange [View article]
    I believe this is the best explanation of the recent SEC filings.
    The new SEC filings are nothing more than re-registration of existing shares to keep them current. Since IMUC is traded on OTC, they are required to re-file S-1 or S-3 every 12 months for all pipe shares or public offering shares. This is not solicitation to sell new shares or new warrants; it essentially has no impact on the company’s cap table.
    The good news is, if you look at the list of shareholders, most investors from last two years are still holding the majority or all of their shares. Some very high quality investors including DAFNA, Straus, and Cummings Bay are playing this long term! These guys are up 150-200 percent!!! They are playing this stock long because they know there is more upside with ICT-107 phase II data.
    Apr 30, 2012. 03:49 PM | Likes Like |Link to Comment
  • Galena Biopharma: How Long Can Big Pharma Wait? [View article]
    Adam---your venom and vengeance certainly triumphed today. You don't care about the the little investors getting hurt today, and obviously care even less about the thousands upon thousands of those suffering from breast cancer.
    Apr 24, 2012. 03:51 PM | 6 Likes Like |Link to Comment
  • Galena Biopharma's Patent Creates Both Immediate And Long-Term Upside [View article]
    It is clear to everyone in the medical and research fields that immunotherapy treatments have great potential. As NeuVax makes progress through the FDA trial process, GALE will continue to gain respect in the healthcare universe. At the end of the day, that is what will drive shareholder value. Price fluctuations will happen, financing deals will happen, bashers will always be around; I bought Galena because of the superior science and the potential markets that the commercialization of NeuVax will be entering. Rumors, speculation and innuendo are for the bashers to post to strike fear, as they short the stock to make a few dollars. As for me, I have no intention of selling for small gains now. The long term outlook and returns are factors that keep me long.
    The members of the Scientific Advisory Board at Galena are some of the best in the field of oncology. Army Col. Dr George Peoples on the GALE team gives me tremendous confidence in the future of this company.
    Good article, thanks for the information.
    Mar 23, 2012. 12:41 PM | 2 Likes Like |Link to Comment
  • Beware: Highly Promoted Galena Biopharma Keeps Moving Higher [View article]
    1. Penny stock newsletters promoting GALE doesn’t mean they were being paid. These newsletters are notorious for picking high moving stocks alongside whatever they are promoting to gain legitimacy. It’s part of their mode of operation and doesn’t mean GALE was involved.
    2. Cytrx and RXII connections are all things from past with a different company and more importantly a different CEO. Cytrx has no ownership of Gale, so any connections are nothing more than farfetched concoctions.
    3. Yes, there is a registration statement (shelf registration) but that has been on for quite some time. In current market environment, every biotech company is trying to raise money. However, that by itself is not a bad thing as it would take the financing risk out of this story. If you look at the list of secondary offerings this year, a number of companies that have raised money this year have appreciated significantly since then.
    4. What Morhamus seems to be missing here is the value of phase III pivotal trial in progress for a major disease with unmet medical need. Should it work, this could be a great opportunity. If it fails, it all goes to zero. However, one should be aware of the timelines involved in phase III before data comes out (3-4 years) and capital that would be required to get there ($50 million plus). Back in January, with a market cap under $25 million, Gale was a screaming undervalued play and stock has appreciated, rightly so, since then. More kudos for people who brought attention to this stock back then.
    5. Articles like this hack piece here should be written more responsibly and with more substance as anyone can scream “Fire” in a theatre and cause panic, which this article seems to have done.
    Mar 23, 2012. 01:56 AM | 7 Likes Like |Link to Comment
  • Galena Investors Are A Strange Brew [View article]
    How do you figure that money will flow from Galena to Cytrx? Cytrx owns no shares of Galena stock.
    Mar 8, 2012. 01:59 PM | 1 Like Like |Link to Comment
  • Galena Investors Are A Strange Brew [View article]
    In your statement of saying:
    "Cytrx, rightly or wrongly, has demonstrated that it is not very sensitive to its subsidiaries shareholders. Its CEO is perceived to be looking after Cytrx first rather than shareholders first. This public perception can be felt in the PPS of anything related to Cytrx."

    This seems to infer that Cytrx has some stake in Galena. I can find no record that they are in any way invested in GALE. Galena is a completely independent company and is by no means a subsidiary of Cytrx of any kind.

    NeuVax has huge upside market potential. Its phase 1 and 2 results have been presented and published at ASCO and the San Antonio Breast Cancer Conference, which are highly recognized venues for peer review. The FDA has given NeuVax an endorsement with the SPA this past December, that alone should clear up any ambiguity of phase 2 results and the promise that the treatment has in eliminating breast cancer recurrence.
    Mar 8, 2012. 04:25 AM | 1 Like Like |Link to Comment